Diagnostics.ai Launches CE-IVDR Certified AI Platform for Molecular Diagnostics
Diagnostics.ai has launched the industry's first CE-IVDR certified transparent AI platform for molecular diagnostics, as announced in a press release. This platform is designed to meet the new EU In Vitro Diagnostic Medical Devices Regulation (IVDR) standards, which emphasize diagnostic accuracy, reproducibility, and algorithm transparency.
The platform, known as PCR.AI, provides algorithmic transparency and per-test auditability for clinical PCR diagnostics. It allows laboratories to understand how AI-generated PCR result analyses are achieved, a significant advancement in molecular-testing machine learning. The technology is backed by over 15 years of experience and has processed millions of samples with over 99.9% accuracy.
Key features of the platform include real-time model monitoring, per-test algorithm accountability, and clinician-ready explanation generation. These features ensure comprehensive auditability and support informed clinical communication, bridging the gap between compliance necessity and clinical confidence.
The PCR.AI platform is now available across Europe, empowering clinical laboratories and diagnostic manufacturers to meet regulatory obligations while enhancing confidence in diagnostic results. It is already in successful use in the U.S., U.K., and other countries, trusted for its reliable and transparent diagnostic performance.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Illumina Launches BioInsight Platform for Genomic Research
TRI Launches TRIAL.OS for Clinical Trial Management
Danaher Plans AI Autonomous Lab for Antibody Research
AI in Clinical Trials Market Forecast to Reach USD 7.32 Billion by 2034
MediSights Reports Study Using AI Agents for Myeloma Market Research
Daily AI Brief: the AI news that matters, in your inbox.